Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Bariatric surgery (BS) is known to improve the components of metabolic syndrome (MS) in obese patients. However, few studies have evaluated the impact of bariatric surgery versus medical therapy (MT) in patients with MS, especially in patients with low body mass index (BMI). This study aimed to assess the effect of bariatric surgery on MS in patients with low BMI by comparing BS (BMI<35 kg/m2 and BMI≥35 kg/m2) with MT (BMI<35 kg/m2). A retrospective study including patients with MS undergoing bariatric surgery and medical therapy at a single institution. We follow up the 5 years effect of bariatric surgery versus medical therapy on the remission of MS, its individual components, atherosclerotic cardiovascular disease (ASCVD) risk, and medication used.
Study design and patients
This study aimed to compare bariatric surgery(BS) with medical therapy (MT) for the management of low BMI patients with MS, approved by the ethics committee and institutional review at our hospital. 100 patients underwent bariatric surgery and 100 patients receiving medical therapy for obesity and type 2 diabetes between 2010 and 2020 at our institution. All patients met the Chinese guidelines developed by the Chinese Society for Metabolic & Bariatric surgery (CSMBS). All patients achieve diagnostic criteria for MS, defined by the presence of at least 3 of the 5 following criteria derived from the joint interim statement (JIS) definition.
outcome and Data collection
All patients follow up the change of improvement in MS and its components following bariatric surgery and medical therapy, including waist circumference, hyperglycemia, hypertension, hyperlipidemia, long-term CVD risk, and medication use
Treatments
3.1 BS group The bariatric surgical procedures performed included Roux-en-Y gastric bypass and sleeve gastrectomy.
3.2 MT group According to the guidelines in China, patients in the medical therapy group received glucose-lowering, lipid-lowering, and antihypertensive medications, with the following targets: glycosylated hemoglobin<7%; systolic blood pressure<140 mmHg, diastolic blood pressure<80 mmHg; low-density lipoprotein cholesterol<2.6 mmol/L; and high-density lipoprotein cholesterol>1.3 mmol/L for female or 1.0 mmol/L for male.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BS group | The group of bariatric surgery therapy in metabolic syndrome patients. |
| |
| MT group | The group of medical therapy in metabolic syndrome patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hypoglycemic drugs | Drug | drug |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in metabolic parameters from baseline to 5 years. | Waist circumference(cm) | baseline to 5 years |
| Change in metabolic parameters from baseline to 5 years. | body mass index(kg/m^2) | baseline to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Change in glycosylated hemoglobin from baseline to 5 years. | glycosylated hemoglobin(%) | baseline to 5 years |
| Change in plasma glucose from baseline to 5 years. | Fasting plasma glucose(mmol/l), |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients underwent bariatric surgery or medical therapy for metabolic syndrome between 2010 and 2020 at our institution.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stryker Laparoscopy | Recruiting | Chongqing | Chongqing Municipality | 400042 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007004 | Hypoglycemic Agents |
| D000959 | Antihypertensive Agents |
| D050110 | Bariatric Surgery |
| ID | Term |
|---|---|
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D002317 | Cardiovascular Agents |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma
| Bariatric surgery | Procedure | surgery |
|
|
| baseline to 5 years |
| Change in blood lipids from baseline to 5 years. | total cholesterol(mmol/l), triglycerides(mmol/l), high-density lipoprotein cholesterol(mmol/l), low-density lipoprotein cholesterol(mmol/l) | baseline to 5 years |
| Changes of CVD risk | 10-year and lifetime ASCVD risk calculated by the China-PAR equation. Evaluation metrics include sex, age, region of residence (South or North), waist circumference, total cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, whether taking antihypertensive drugs, whether diabetic, whether smoker, family history of cardiovascular and cerebrovascular. | baseline to 5 years |
| Hypoglycemic drugs use | The number and daily drug dose of hypoglycemic drugs | baseline to 5 years |
| Antihypertensive drugs use | The number and daily drug dose of antihypertensive drugs | baseline to 5 years |
| Lipid-lowering drugs use | The number and daily drug dose of lipid-lowering drugs | baseline to 5 years |
| D009750 |
| Nutritional and Metabolic Diseases |
| D045506 | Therapeutic Uses |
| D049088 | Bariatrics |
| D000073319 | Obesity Management |
| D013812 | Therapeutics |
| D013514 | Surgical Procedures, Operative |